As CD4+ T helper cells have been shown to significantly contribute to boosting anti-tumor cytoxicity [51], a co-transfer of CD4+ and CD8+ T cells can be envisaged as being part of optimized ACT protocols. This evidence concerns the gene CD4 and neoplasm.